Protocolli GOIRC-sponsored in attivazione
GOIRC-01-2022 HEROS (OSSERVAZIONALE)
HER2 aberrations in advanced NSCLC: an Observational, retrospective and prospective, multi-centric Study exploring HER2 alterations incidence and therapeutic management in Italy
Centro Coordinatore: Parma
GOIRC-01-2023 CARRY-ON
Continued PD-L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first-line platinum-etoposide chemotherapy and a PD-L1 inhibitor – CARRY ON study
Centro Coordinatore: Bologna
GOIRC-01-2024 PRELUDE
Pembrolizumab plus lenvatinib in REcurrent ccRCC patients failing permbroLizUmab aDjuvant trEatment: PRELUDE Trial – GOIRC-01-2024
Centro Coordinatore: Terni
GOIRC-02-2024 IMMUNOSTAR
Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial – GOIRC-02-2024
Centro Coordinatore: Reggio Emilia
GOIRC-03-2024 REMAIN
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in radically resected EGFR-mutated NSCLC patients: REMAIN study – GOIRC-03-2024
Centro Coordinatore: Parma
GOIRC-04-2024 CECYDE
A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial – GOIRC-04-2024
Centro Coordinatore: Lucca